Catalyst Wire Dossier Catalyst Wire Dossier

Zanubrutinib (Brukinsa)

zanubrutinib · BeiGene
Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for Zanubrutinib (Brukinsa), covering 2024-07-18 to 2026-02-18. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma [Phase 2]

See pricing